PRA 216
Alternative Names: PRA-216Latest Information Update: 11 Sep 2026
At a glance
- Originator Prana Therapies
- Class Anti-inflammatories; Antiasthmatics; Bispecific antibodies
- Mechanism of Action Interleukin 4 receptor alpha subunit antagonists; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Chronic obstructive pulmonary disease
- Phase I/II Asthma
Most Recent Events
- 08 Sep 2026 Phase-II clinical trials in Atopic dermatitis (Treatment-experienced) (SC) (NCT07810777)
- 08 Sep 2026 Phase-II clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) (SC) (NCT07730281)
- 08 Sep 2026 Pharmacodynamic, pharmacokinetic, and adverse event data data from a phase I trial in Asthma released by Prana Therapies